Data Presented at ASCO Finds REVLIMID as a Monotherapy is Effective and Well-Tolerated for Previously Treated Multiple Myeloma Patients

Data Presented at ASCO Finds REVLIMID as a Monotherapy is Effective and Well-Tolerated for Previously Treated Multiple Myeloma Patients
BUSINESS WIRE--The Moffitt Cancer Center today said findings from a clinical trial presented at the American Society of Clinical Oncology (ASCO) meeting evaluating REVLIMID (lenalidomide) as a monotherapy is both effective and well-tolerated in patients who have been previously treated for multiple myeloma with two or more therapies...